menu search

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD (teplizumab-mzwv) to a wholly-owned subsidiary […] The post MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million appeared... Read More
Posted: Mar 8 2023, 22:36
Author Name: forextv
Views: 103183

Search within

Pages Search Results: